Risultati per: Nuovi possibili trattamenti per il morbo di Alzheimer

A randomized trial failed to replicate positive findings seen with a related drug, citalopram, and showed the same troubling side effects.

Disponibili i risultati del primo trial clinico dopo 52 settimane

Disponibili i risultati del primo trial clinico dopo 52 settimane

Disponibili risultati primo trial clinico dopo 52 settimane

La fase Rem carente riduce il volume di un’area del cervello

This cohort study evaluates the association between extreme heat and the risk of hospitalization with Alzheimer disease and related dementias in the US.

The ATR-FTIR (Attenuated Total Reflectance-Fourier Transform Infrared) plasma spectra features can identify AD-related pathological changes. These spectral features serve as digital biomarkers, providing valuable support in the early screening and diagnosis of AD.

To the Editor In their excellent research, Dr Palmqvist and colleagues report high diagnostic accuracy of blood biomarkers in the diagnosis of Alzheimer disease. The authors used the STROBE checklist for observational studies, but this is a prospective diagnostic accuracy study, for which the STARD checklist is more appropriate.

In Reply We appreciate the opportunity to respond to Dr Mintzker’s thoughtful comments regarding our study on the diagnostic accuracy of blood biomarkers for the detection of Alzheimer disease.

Andreoni, ‘sovrainfezioni da più batteri a causa del prolungarsi del suo stato’

‘Ministero continuerà a sostenere la ricerca in questo settore’

Airalzh Onlus comunica l’apertura di altri due bandi nel 2025

Ministero Salute ha assegnato finanziamento di 1,2 milioni euro

Stroke, Volume 56, Issue Suppl_1, Page ATP393-ATP393, February 1, 2025. Dysregulation of the immune system is a contributing factor in the progression of Alzheimer’s Disease (AD), likely by increased vascular inflammation triggered by brain or peripheral inflammation. Our research has demonstrated that neutrophils play a role in causing hypoperfusion by adhering to and obstructing blood vessels, as seen in both mouse models for and patients with AD. Notably, protein glycosylation of membrane proteins is essential for regulating the adhesion properties of neutrophils to immune cells and the vasculature.Here, we utilize lectin blots to show that sialic acid residues, which are the terminal caps of glycosylation chains, are increased on neutrophil membrane proteins from an amyloidosis Alzheimer’s mouse model. Furthermore, we evaluated the efficacy of the sialyltransferase inhibitor alpha 2,3 sialyltransferase-IN-1 by lectin blot analyses, identifying it to be an effective compound for removing sialic acid from neutrophil membrane proteins. Notably, we performedin vivomultiphoton imaging of cerebral blood flow and capillary stalling in AD mice injected with alpha 2,3 sialyltransferase-IN-1. Our findings demonstrated that reducing sialic acid residues on neutrophils improved cerebral blood flow and capillary stalling.This work suggests that the altered glycosylation pattern, specifically aberrant sialylation residues of neutrophil glycoproteins, are a significant contributing factor to the hypoperfusion observed in AD mouse models and patients. Modulating the glycosylation profile may present a potential therapeutic approach for improving the vascular dysfunction associated with AD pathogenesis.